Mr. Jeffrey Stevens reports

PSYCHED WELLNESS HIGHLIGHTS U.S. FEDERAL POLICY MOMENTUM SUPPORTING PSYCHEDELIC SECTOR

Psyched Wellness Ltd. today highlighted recent United States federal policy developments supporting psychedelic research and outlines the potential implications for the sector and the company.

Recent announcements by U.S. President Donald Trump include an executive order designed to accelerate research, development and regulatory review of psychedelic compounds for medical use. The initiative targets significant unmet needs in mental health treatment, including posttraumatic stress disorder, depression and addiction.

The policy direction includes the evaluation of expedited clinical pathways, expanded access programs and potential rescheduling of compounds that demonstrate safety and efficacy. Management believes these actions represent a meaningful shift toward broader federal engagement with the category.

CEO commentary: "We believe this marks a significant step forward for the sector," said Jeff Stevens, chief executive officer of Psyched Wellness. "Increased federal support in the United States has the potential to accelerate research, attract new capital and further legitimize the broader category of mushroom-derived compounds. As awareness and acceptance continue to build, we expect these developments to contribute to stronger consumer engagement and long-term growth opportunities across the space. Psyched Wellness is well positioned to participate in this momentum through our focus on Amanita muscaria-derived consumer products."

Sector impact

Management believes current U.S. policy momentum may:

• Accelerate the pace of scientific and clinical advancement;
• Drive increased investor attention and capital formation;
• Support normalization and broader market acceptance;
• Expand long-term commercial pathways across multiple segments.

Positioning of Psyched Wellness

Psyched Wellness remains focused on the development and commercialization of Amanita muscaria-derived consumer products. The company believes that increased regulatory engagement and visibility at the federal level may act as a catalyst for:

• Expanding consumer awareness of mushroom-based wellness categories;
• Strengthening demand for differentiated science-backed products;
• Enhancing strategic and partnership opportunities.

The company continues to monitor regulatory developments and assess opportunities aligned with its commercial strategy

About Psyched Wellness Ltd.

Psyched Wellness is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category.

We seek Safe Harbor.